ABSTRACT

The results of HERS do not support the

beneficial effect of HRT in secondary

prevention of CVD.17 This well-designed

randomized, double-blind, placebo-controlled

study evaluated the role of continuous

oestrogen (conjugated equine oestrogen)

plus progestin (medroxyprogesterone acetate)

in preventing recurrent CVD events in

2763 women with documented coronary

disease.